"Bayer AG, German largest pharmaceutical company, has reached an agreement with the Finnish Algeta ASA Scandinavian company to make the payment of $ 800 million for the rights to manufacture the drug Alpharadin, the new experimental drug therapies for cancer", - reports Bloomberg.
"These days the drug is on the third and final testing stage required to obtain the license, and it is being tested in the treatment of metastatic
prostate cancer in bone tissue", - said Bayer report.
In accordance with the terms and conditions of the Agreement Algeta shall receive $ 61 million in cash, as well as royalties on sales that are directly dependent on the continued success of the drug. In addition, the companies agreed to jointly fund further research to improve the product, and Bayer shall bear the brunt.
"Alpharadin with active ingredient as chloride of radium-223 should be input intravenously once a month for 4-6 months and it affects tumor directed alpha radiation with non-affecting healthy tissue around it. It could also be used in the treatment of other cancer forms, giving metastases in bone tissue", - believed the representatives of Bayer.
"The data that we obtained, suggest that Alpharadin is the drug of directed action, easy to use and with acceptable side effects", - said Kemal Malik, Bayer Manager.
Main cure for cancer that is manufactured by Bayer at the present time is the drug named Nexavar. It is used primarily to treat cancer of the kidneys and liver, and it has significant undesirable effects.
I got to say.... Your service is absolutely superb! I just received my order in the mail. You have just gotten yourself a steady very impressed satisfied customer. Thank you for your excellent service.
Print page